What stem cell therapy cost can include

A written quote should show the full cost

The quote should name the exact procedure and sore joint. It should include the exam, each visit, and later care. Find out whether the total pays for one treatment or several. You'll also need the deposit and cancellation rules.

Read every line before you sign. A low first amount can leave out later visits. You don't want a surprise bill after care starts. Take the quote home if you need time.

Insurance may cover other parts of care

Call your health plan before you agree to treatment. Use the exact procedure name from the quote. Ask whether the exam and later care have coverage. The blood or marrow procedure may still need direct payment.

A covered office visit doesn't cover every service. Get the plan's answer in writing when you can. Then set it beside the clinic's written quote. This helps you see which bill is yours.

Price alone can't tell you what fits

Price alone doesn't show whether care fits your joint. Your exam, daily limits, and past care matter more. Ask what relief the clinician expects and when it may wear off. Find out what care follows when relief doesn't come.

One option at QC Kinetix is PRP, a regenerative treatment made by gathering platelets from your blood and putting the prepared portion into your sore joint. The clinic can't leave you guessing why that procedure fits your exam. It should also name the full cost and likely visits. You can leave and decide later.

Sources

1. An analysis of 38 businesses advertising stem cell and exosome products for COVID-19 found listed prices from $2,950 to $25,000 with an average of $11,322 - a direct measure of what this marketplace charges for products with no regulatory approval.

   Turner L, et al. — Businesses marketing purported stem cell treatments and exosome therapies for COVID-19: An analysis of direct-to-consumer online advertising claims. Stem Cell Reports, 2023. DOI: 10.1016/j.stemcr.2023.09.015.

2. In orders issued 26 December 2024 and announced 8 January 2025, a federal court permanently banned the co-founders of the Stem Cell Institute of America and their companies from marketing any regenerative medicine treatment, and ordered $5,155,146 in refunds and civil penalties. The court found on summary judgment that they published false and misleading advertisements about the efficacy and approval of stem cell injections for osteoarthritis, neuropathy and joint pain; their clinic charged up to $5,000 per injection and the customers were almost exclusively elderly and disabled people.

   US Federal Trade Commission — Stem Cell Institute Co-Founders and Companies Banned from Marketing Stem Cell Treatments and Ordered to Pay More Than $5.1 Million for Refunds and Civil Penalties. , 2025.

3. In October 2018 the FTC settled charges against a California physician and two companies that earned at least $3.31 million selling 'amniotic stem cell therapy' between 2014 and 2017 - initial injections cost $9,500 to $15,000 with booster treatments at $5,000 to $8,000 - for advertising, without evidence, that it treated Parkinson's disease, autism, macular degeneration, cerebral palsy, multiple sclerosis and osteoarthritis.

   US Federal Trade Commission — FTC Stops Deceptive Health Claims by a Stem Cell Therapy Clinic. , 2018.

4. A 2016 analysis of internet marketing found widespread direct-to-consumer promotion of unapproved stem cell interventions by businesses based in the United States - not only in countries with lax medical regulation - and concluded regulators must better oversee the marketplace.

   Turner L, et al. — Selling Stem Cells in the USA: Assessing the Direct-to-Consumer Industry. Cell Stem Cell, 2016. DOI: 10.1016/j.stem.2016.06.007.

5. Hundreds of US businesses and clinics market unproven and unlicensed stem cell-based interventions, and many of them appear to violate the federal regulations that govern human cell and tissue products.

   Turner L, et al. — The US Direct-to-Consumer Marketplace for Autologous Stem Cell Interventions. Perspect Biol Med, 2018. DOI: 10.1353/pbm.2018.0024.

6. FDA states in its consumer alert that the only FDA-approved stem cell products in the United States are blood-forming stem cells derived from umbilical cord blood, approved for disorders of the blood-forming system, and that NONE of these products - stem cells, stromal vascular fraction, umbilical cord blood, Wharton's jelly or amniotic fluid - has been approved for the treatment of any orthopedic condition, including osteoarthritis, tendonitis, disc disease, tennis elbow, back pain, hip pain, knee pain, neck pain or shoulder pain.

   US Food and Drug Administration, Center for Biologics Evaluation and Research — Consumer Alert on Regenerative Medicine Products Including Stem Cells and Exosomes. , 2020.